Erik Swain

Young children at high genetic risk for type 1 diabetes may be more likely to progress to the disease based on their dietary intake, according to a presenter at the European Association for the Study of Diabetes annual meeting.

Children with obesity receiving once-daily liraglutide 3 mg had a greater reduction in BMI at 56 weeks than those receiving placebo, according to data presented at the European Association for the Study of Diabetes annual meeting.

Adults with type 2 diabetes at high risk for cardiovascular events were more likely to sustain an HbA1c of 6.5% or less at 2 years with tirzepatide if they lost more weight and had improved beta-cell function, according to new data. As Healio previously reported, tirzepatide (Mounjaro/Zepbound, Eli Lilly) conferred greater reductions in HbA1c and body weight at 1 year than insulin glargine for

Mass ECG screening for atrial fibrillation in older adults did not reduce the incidence of stroke or stroke hospitalization, according to the results of two trials presented at the European Society of Cardiology Congress.In the GUARD-AF study, screening U.S. adults from primary care practices aged 70 years or older for AF did not reduce risk for stroke compared with the usual care.

In patients with atrial fibrillation and heart failure with reduced ejection fraction, cryoballoon ablation was noninferior to radiofrequency ablation, according to the results of the CRABL-HF trial.

Not fasting before cardiac catheterization procedures with conscious sedation was noninferior and likely superior to fasting for safety, and improved patient satisfaction, researchers reported at the European Society of Cardiology Congress.

Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone improved outcomes compared with placebo regardless of baseline diabetes status, according to new data from the FINEARTS-HF trial.

For older adults with non-STEMI, routine coronary intervention was safe but did not lower risk for death from CV causes or nonfatal MI compared with medical therapy alone, according to new data from the SENIOR-RITA trial.“Our study, in a sense, provides a foundation for older heart attack patients and their clinicians to make informed decisions about whether they need to undergo invasive

Patients with atrial fibrillation needing stroke prevention assigned to abelacimab had very low rates of bleeding during invasive procedures, according to new data from the AZALEA-TIMI 71 trial.